ALBUQUERQUE, N.M.--Dr. Edward R. Flynn Ph.D., founder of Senior Scientific, LLC, a company owned by Manhattan Scientifics (OTCBB:MHTX), has been prominently mentioned in the October issue of The America Physics Society Journal for his work in cancer detection.
Manhattan Scientifics announced in June the acquisition of Senior Scientific LLC to commercialize the groundbreaking tools for cancer detection, diagnosis and treatment originated by new nanotechnology tools that can detect tumors and metastases much earlier than currently possible. The technology also has the capability to measure and locate tumors more precisely than ever before. The technology can enable personalized and precise treatment since it can identify the exact type of cancer cells present, allowing doctors to design treatments for the exact type and extent of cancer present.
The APS Journal article said, “Edward Flynn, a nuclear physicist who worked at Los Alamos National Laboratory for 38 years, saw a problem and knew his unique skill set could help conquer it. His wife was diagnosed with breast cancer and he pondered whether he could develop a better detection tool using nanoparticles and magnetic sensors. He created a technique in which a patient is injected with iron oxide nanoparticles coated with antibodies, which adhere to specific cancer cells present in a tumor. The patient is then subjected to a small magnetizing field that aligns the metal nanoparticles and when the field is discontinued, the nanoparticles emit a magnetic signal. This emitted signal is detected by superconducting quantum interference device (SQUID) sensors. The resulting signal measurement can show doctors 'how many metal particles, and therefore how many cancer cells, are present, and where in the breast they are located,' according to a recent article featuring Flynn by Shirley S. Wang in The Wall Street Journal.”
The APS Journal noted that Dr. Flynn’s innovation requires only a very small number of cancerous cells to be present, approximately 100,000, as opposed to several million cells needed for a mammogram. This means the system can detect a breast cancer tumor with 100% accuracy up to three years earlier than a mammogram can. Dr. Flynn’s technology also greatly enhances the ability to more closely monitor the number of cancer cells.
The APS Journal noted that Dr. Flynn is working with Manhattan Scientifics to commercialize his technology and bring it to market.
Manhattan Scientifics, Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of disruptive technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.